- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of July 31
The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of July 31, 2017.
Transcript
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of July 31.
Number 5: A recent survey of Canadian patients highlights serious concerns about automatic substitution of biosimilars for reference products.
Number 4: Biosimilar developer Coherus has moved for a stay of discovery in its BPCIA litigation over pegfilgrastim, citing the company’s need to preserve its resources.
Number 3: The FDA Reauthorization Act of 2017 was passed by the Senate on Thursday. The must-pass bill reauthorizes user fees for biosimilar applicants.
Number 2: It was a busy week for trastuzumab biosimilars, with biologics license applications filed by Amgen and Allergan as well as Celltrion and Teva.
And Number 1: Brian Lehman takes a close look at the potential impact of Merck’s launch of Renflexis at a 35% discount off the list price of the reference, Remicade, in the US marketplace.
Finally, last week, our newsletter asked you to share your thoughts on how great a discount payers are expecting for biosimilar products. To view results of the poll, follow The Center for Biosimilars® on LinkedIn.
To sign up for our weekly newsletter or to read these articles and more, visit www.centerforbiosimilars.com.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Escaping the Void: All Things Biosimilars With Craig & G
August 1st 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
